

Resource Summary Report

Generated by PRECISE-TBI on Jul 30, 2026

CFTR2

RRID:SCR_019078

Type: Tool

Proper Citation

CFTR2 (RRID:SCR_019078)

Resource Information

URL: <https://cftr2.org/>

Proper Citation: CFTR2 (RRID:SCR_019078)

Description: International initiative led by team of researchers and clinicians and supported by the US Cystic Fibrosis Foundation that seeks to provide complete, advanced and expert reviewed functional and clinical information on CFTR mutations. Provides information for patients, researchers, and general public about specific variants. For each variant or variant combination included in database, website will provide information about whether variant or variant combination is CF-causing, and information about sweat chloride, lung function, pancreatic status, and Pseudomonas infection rate in patients in CFTR2 database with this variant or variant combination.

Synonyms: Clinical and Functional TRAnslation of CFTR, cftr2, Clinical and Functional TRAnslation 2

Resource Type: disease-related portal, data or information resource, database, topical portal, portal

Keywords: CF gene, cystic fibrosis gene, functional testing, CFTR2 variant, data, CFTR mutations, clinical information, , FASEB list

Related Condition: cystic fibrosis

Availability: Free, Freely available

Resource Name: CFTR2

Resource ID: SCR_019078

License URLs: <https://cftr2.org/sites/default/files/Legal-Terms-Conditions-CFTR2.pdf>, <https://cftr2.org/sites/default/files/Privacy-Policy-CFTR2.pdf>

Record Creation Time: 20220129T080343+0000

Ratings and Alerts

No rating or validation information has been found for CFTR2.

No alerts have been found for CFTR2.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 127 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Lu Y, et al. (2025) Cystic fibrosis-causing variants in Chinese patients with congenital absence of the vas deferens: a cohort and meta-analysis. Asian journal of andrology, 27(5), 611.

Kireeva TN, et al. (2025) Cystic fibrosis therapy: from symptoms to the cause of the disease. Vavilovskii zhurnal genetiki i selektsii, 29(2), 279.

Tedman A, et al. (2025) General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants. eLife, 14.

Li J, et al. (2025) The CFTR K464N variant in fetuses potential increases premature birth risk in Chinese families. Human genomics, 19(1), 25.

Farrell PM, et al. (2025) Reflections on 50 Years of Cystic Fibrosis Newborn Screening Experience with Critical Perspectives, Assessment of Current Status, and Predictions for Future Improvements. International journal of neonatal screening, 11(4).

Tedman A, et al. (2025) General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants. bioRxiv : the preprint server for biology.

Yin X, et al. (2025) Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Nature communications, 16(1), 2214.

Pinnaro CT, et al. (2025) Unbalanced long-chain fatty acid beta-oxidation in newborns with cystic fibrosis and congenital hypothyroidism. Molecular genetics and metabolism reports, 42, 101182.

Demchenko A, et al. (2025) Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening. International journal of molecular sciences, 26(2).

Nov-Klaiman T, et al. (2025) More of the same? Israel's expanded carrier screening for cystic fibrosis. *European journal of human genetics : EJHG*, 33(12), 1555.

Chandane P, et al. (2025) Clinical and genetic profiles of paediatric patients with cystic fibrosis from Western India. *Lung India : official organ of Indian Chest Society*, 42(2), 103.

Specht C, et al. (2025) An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations. *Nucleic acids research*, 53(12).

Bu H, et al. (2025) Clinical and genetic characteristics of diseases caused by CFTR gene mutations in 15 Chinese children: a retrospective analysis. *BMC pediatrics*, 25(1), 701.

Walters S, et al. (2025) From past to progress: a retrospective study on CFTR genetic testing in South Africa. *Journal of community genetics*, 16(6), 827.

Nicosia L, et al. (2025) Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids. *iScience*, 28(3), 111979.

Terlizzi V, et al. (2025) Cystic fibrosis: new challenges and perspectives beyond ellexacaftor/tezacaftor/ivacaftor. *Therapeutic advances in respiratory disease*, 19, 17534666251323194.

Romeo E, et al. (2025) Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector. *Journal of medicinal chemistry*, 68(4), 4596.

McGarry ME, et al. (2025) Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation. *International journal of neonatal screening*, 11(2).

Green DM, et al. (2025) Next-Generation Sequencing for Cystic Fibrosis: Florida Newborn Screening Experience. *International journal of neonatal screening*, 11(4).

Kerschner JL, et al. (2024) The impact of genomic distance on enhancer-promoter interactions at the CFTR locus. *Journal of cellular and molecular medicine*, 28(4), e18142.